BLFS BioLife Solutions Inc.

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Date	Price Target	Rating	Analyst
9/30/2024	$29.00	Buy	H.C. Wainwright
4/4/2024	$22.00	Buy	Jefferies
7/11/2023	$29.00	Buy	Craig Hallum
4/25/2022	$28.00	Perform → Outperform	Oppenheimer
10/19/2021	$61.00	Buy	B. Riley Securities
10/15/2021	$64.00	Outperform	Cowen
8/13/2021	$50.00 → $60.00	Overweight	Keybanc

BioLife Solutions Inc.

Recent Analyst Ratings for BioLife Solutions Inc.

BioLife Solutions Inc. SEC Filings

SEC Form 10-Q filed by BioLife Solutions Inc.

BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.

BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-K filed by BioLife Solutions Inc.

BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

BioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

SEC Form 10-Q filed by BioLife Solutions Inc.

BioLife Solutions Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Human Resources Officer Aebersold Sarah sold $15,806 worth of shares (711 units at $22.23), decreasing direct ownership by 0.90% to 78,721 units (SEC Form 4)

Large owner Casdin Partners Master Fund, L.P. sold $23,800,000 worth of shares (1,000,000 units at $23.80) (SEC Form 4)

Chief Marketing Officer Berard Todd sold $8,579 worth of shares (362 units at $23.70), decreasing direct ownership by 0.27% to 134,922 units (SEC Form 4)

EVP & Chief Scientific Officer Mathew Aby J. sold $15,097 worth of shares (637 units at $23.70), decreasing direct ownership by 0.18% to 353,118 units (SEC Form 4)

Chief Financial Officer Wichterman Troy sold $24,695 worth of shares (1,042 units at $23.70), decreasing direct ownership by 0.56% to 186,685 units (SEC Form 4)

Chief Technology Officer Werner Sean sold $1,540 worth of shares (65 units at $23.70), decreasing direct ownership by 0.23% to 27,610 units (SEC Form 4)

Chief Human Resources Officer Aebersold Sarah sold $5,570 worth of shares (235 units at $23.70), decreasing direct ownership by 0.29% to 79,432 units (SEC Form 4)

Chief Quality and Operations Foster Karen A. sold $7,584 worth of shares (320 units at $23.70), decreasing direct ownership by 0.16% to 194,996 units (SEC Form 4)

Chief Quality and Operations Foster Karen A. sold $5,637 worth of shares (251 units at $22.46), decreasing direct ownership by 0.13% to 195,316 units (SEC Form 4)

Chief Human Resources Officer Aebersold Sarah sold $4,874 worth of shares (217 units at $22.46), decreasing direct ownership by 0.27% to 79,667 units (SEC Form 4)